Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology oligoDOM® inducing powerful CD8 T-cell responses
Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, in order to accelerate the development of oligoDOM® technology platform.
Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, in order to accelerate the development of oligoDOM® technology platform.
oligoDOM® technology platform capitalizes on:
Osivax lead program is a game-changing universal influenza vaccine
Osivax relies on an international team with complementary life science experiences and a prestigious international Scientific Advisory Board with industry and academic expertise
Osivax is based in Lyon (France) and Liège (Belgium), the two clusters of vaccine R&D in Europe.
Osivax remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens
(1) Hayward AC, Wang L, Goonetilleke N, et al. Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015;191(12):1422-1431. doi:10.1164/rccm.201411-1988OC.
- More than 12 years of R&D on a breakthrough approach to induce CD8 T-cell immunity
- Clinical package developed by OSIVAX on a universal influenza vaccine candidate
- Clinical and preclinical data generated by leading independent teams in Europe (Oxford University, DKFZ / Heidelberg University, Inserm / CNRS...)
Osivax lead program is a game-changing universal influenza vaccine
- Leveraging oligoDOM® technology, Osivax’s team is developing a standalone recombinant vaccine to prevent moderate to severe cases of seasonal and pandemic influenza
- This oligoDOM®-based universal influenza vaccine induces powerful CD8 T-cell immune responses against the highly conserved flu NucleoProtein (NP) and won’t require annual updates as NP is a highly conserved antigen
- The aim of this universal Influenza vaccine is to provide greater than 70% protection from morbidity and mortality caused by current and future A- and B-strain influenza viruses (1)
- Osivax universal vaccine program is currently in phase I clinical trial, actively preparing a phase IIa
Osivax relies on an international team with complementary life science experiences and a prestigious international Scientific Advisory Board with industry and academic expertise
Osivax is based in Lyon (France) and Liège (Belgium), the two clusters of vaccine R&D in Europe.
Osivax remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens
(1) Hayward AC, Wang L, Goonetilleke N, et al. Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015;191(12):1422-1431. doi:10.1164/rccm.201411-1988OC.